Wordt geladen...
Ribociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR+/HER2– Advanced Breast Cancer
In an updated analysis from the phase III MONALEESA‐3 trial with more than 4.5 years of follow‐up, ribociclib plus fulvestrant maintained a significant overall survival benefit compared with fulvestrant alone in postmenopausal women with HR‐negative, HER2‐positive advanced breast cancer.
Bewaard in:
| Gepubliceerd in: | Oncologist |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley & Sons, Inc.
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8262304/ https://ncbi.nlm.nih.gov/pubmed/34152031 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13866 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|